The phosphatidylinositol-3-kinase (PI3K) and AKT (protein kinase B) signaling pathways play an important role in regulating cell cycle progression and cell survival. In previous studies, we demonstrated that AKT is activated in HTLV-1-transformed cells and that Tax activation of AKT is linked to p53 inhibition and cell survival. In the present study, we extend these observations to identify regulatory pathways affected by AKT in HTLV-1-transformed cells. We demonstrate that inhibition of AKT reduces the level of phosphorylated Bad, an important member of the proapoptotic family of proteins. Consistent with the decrease of phosphorylated Bad, cytochrome c is released from the mitochondria and caspase-9 is activated. Pretreatment of the cells with caspase-9 specific inhibitor z-LEHD-FMK or pan caspase inhibitor Ac-DEVD-CHO prevented LY294002-induced apoptosis. Of interest, p53 siRNA prevents LY294002-induced apoptosis in HTLV-1-transformed cells, suggesting that p53 reactivation is linked to apoptosis. In conclusion, the AKT pathway is involved in targeting multiple proteins which regulate caspase-and p53-dependent apoptosis in HTLV-1-transformed cells. Since AKT inhibitors simultaneously inhibit NF-κB and activate p53, these drugs should be promising candidates for HTLV-1-associated cancer therapy. Published by Elsevier Inc.
Introduction
AKT, also known as protein kinase B (PKB), is a serine/ threonine kinase and the primary mediator of PI3K-initiated signaling. AKT and upstream PI3K have a number of substrates that contribute to malignant transformation (Chang et al., 2003) and have been associated with diverse human cancers including prostate, breast, lung, melanoma and leukemia (Lin et al., 1999; Fry, 2001; Lin et al., 2001; Krasilnikov et al., 1999; MartinezLorenzo et al., 2000; Nicholson and Anderson, 2002) . AKT plays a crucial role in a variety of cellular events such as apoptosis, cell cycle progression and transcriptional regulation (Brazil et al., 2004 ). AKT's ability to prevent apoptosis in some cells is established through phosphorylation and inhibition of pro-apoptotic mediators such as Bad and caspase-9 (Datta et al., 1999) . In other situations, AKT activates the transcription factor CREB, and the IκB kinase (IKK), a positive regulator of NF-κB, to regulate the expression of genes with anti-apoptotic activity (Fresno Vara et al., 2004) . AKT also affects cell cycle progression by regulating cyclin D function. This is accomplished by phosphorylation of p27 and p21 by AKT. Phosphorylation restricts these proteins to the cytoplasm, effectively segregating the cell cycle inhibitors from CDK-cyclin complexes (Collado et al., 2000; Zhou et al., 2001 ).
Human T cell lymphotrophic virus type 1 (HTLV-1) is the etiologic agent of adult T cell leukemia (ATL) and chronic inflammatory diseases such as HTLV-1-associated myelopathy/ tropical spastic paraparesis (HAM/TSP) (Poiesz et al., 1980; Seiki et al., 1983; Gessain et al., 1985; Osame et al., 1986) .
Available online at www.sciencedirect.com Virology 370 (2008) 264 -272 www.elsevier.com/locate/yviro HTLV-1 encodes a 40-kDa protein, Tax, which is critical for viral replication, transformation and gene regulation (Akagi et al., 1995; Grassmann et al., 1989; Nerenberg et al., 1987; Tanaka et al., 1990) . Tax interferes with cell growth control pathways through direct interaction with regulatory proteins and regulation of critical transcription pathways including NF-κB, CREB, SRF, E2F and AP-1 (Xiao et al., 2001; Lemasson et al., 1998; Iwai et al., 2001; Suzuki et al., 1999) . Tax also inhibits the transcription function of the tumor suppressor p53, inhibiting its ability to respond to cellular stress signals (Cereseto et al., 1996; Mulloy et al., 1998; Pise-Masison et al., 2001 . Furthermore, we have shown that Tax activates AKT, which is linked to NF-κB activation, p53 inhibition and cell survival (Jeong et al., 2005b) . The AKT signaling pathway is believed to contribute to the maintenance of the latent state by suppressing apoptosis and thereby preventing the elimination of virus-infected cells. Our laboratory was the first to demonstrate that AKT is activated in HTLV-1-transformed cells and is phophorylated at S473 and T308 (Jeong et al., 2005b) . These results were confirmed by Ikezoe et al. who further showed that the upstream mTOR pathway was activated in HTLV-1-transformed cells (Ikezoe et al., 2007) . In the present study, we extend these observations to define downstream regulatory pathways which are regulated by AKT in HTLV-1-transformed cells. Our results demonstrated that blocking AKT reduced phosphorylation of Bad, increased cytochrome c release and activated the caspase-9 apoptosis pathway. Of interest, inhibition of p53 through an adenovirus p53 siRNA demonstrated that p53 played an important role in the apoptosis pathway induced by AKT inhibition.
Results

Inhibition of AKT by LY294002 and AKT inhibitor II results in cell death in HTLV-1-transformed cells
In previous studies, we demonstrated that Tax activates AKT and that treatment of HTLV-1-transformed cells with LY294002 inhibited AKT activity (Jeong et al., 2005b) . To gain a more complete understanding of the importance of the activated AKT pathway in HTLV-1-transformed cell lines, C81, MT-2 and Hut102 were cultured with increasing concentrations of the PI3K/AKT inhibitor LY294002. Cells were harvested and analyzed for cell viability using the ATP CellTiter-Glo assay. The results presented in Fig. 1A demonstrate that, upon treatment with LY294002, cell viability decreased in a concentration dependent manner (Fig. 1A) . MT-2 and Hut102 were the most sensitive to the PI3K/AKT inhibitor followed by C81 cells. In a parallel set of experiments, we determined that cell death increased with time (data not shown). Thus, a concentration-and time-dependent cell death response to LY294002 treatment was observed.
To provide further evidence for the role of AKT in HTLV-1 in cell survival, we analyzed the effect of specific AKT inhibitor II. The inhibitor is a phosphatidylinositol analog that inhibits the activation of AKT without decreasing phosphorylation of upstream kinase PDK-1. C81, Hut102 and MT-2 cells were incubated with 0, 20, 40 or 80 μM AKT inhibitor II for 48 h. Cells were harvested and analyzed for cell viability using the ATP CellTiter-Glo assay. The results presented in Fig. 1B demonstrate that inhibition of AKT leads to a dose-dependent increase in cell death. We next determined if cell death was time dependent. C81, Hut102 and MT2 cells were treated with AKT inhibitor II at a concentration of 20 or 40 μM. An aliquot of cells was harvested at 0, 24, 48, 72 and 96 h and analyzed for cell viability using the ATP CellTiter-Glo assay. The results presented in Fig. 1C demonstrate that there was a timedependent increase in cell death following treatment with the specific AKT inhibitor. Because of the cost of AKT inhibitor II, all subsequent studies were done with AKT inhibitor LY294002.
Alteration in cell cycle and p27 expression following inhibition of AKT
We next analyzed the effect of AKT inhibition on cell cycle distribution by FACS analysis. Cell cycle analysis of the C81, MT-2 and Hut102 cells following treatment with LY294002 demonstrated an accumulation of cells in G1 and an increase in sub-G1 cells ( Fig. 2A ; data not shown). By 18 h after treatment with LY294002, the percentage of cells in sub-G1 increased from 2.7 to 21%. A similar increase in the percentage of sub-G1 cells was observed in the analysis of MT-2 and Hut102 cells (data not shown). We also noted that the percentage of cells in G1 increased by 18 h post treatment ( Fig. 2A) .
Consistent with the accumulation of cells in G1, western blot analysis of C81 cell extracts demonstrated that the level of cdk inhibitor p27 increased dramatically, while the level of cyclin D1 decreased (Fig. 2B) . A similar increase in p27 protein was observed following treatment of Hut102 cells with AKT inhibitor LY294002 (Fig. 2C ). While the increase in p27 protein is under investigation, the decrease in cyclin D1 expression is likely the result of inhibition of the NF-κB signaling pathway by LY294002 (Joyce et al., 1999; Hinz et al., 1999; Guttridge et al., 1999; Jeong et al., 2005b) . In contrast to these two proteins, the level of p21 and cyclin E remained relatively constant throughout the treatment (Fig. 2B ). The level of control protein actin remained constant throughout the time course (Fig. 2B ).
Analysis of Bcl-2 family members, Bad phosphorylation and cytochrome c release following treatment with LY294002
To gain greater insight into the apoptosis pathway induced by LY294002, we analyzed the protein expression of Bcl-2 family members including pro-apoptotic Bad and Bax. Since all the HTLV-1-transformed cell lines had reacted similarly to the AKT inhibitors, we chose C81 cells for a more in depth mechanistic analysis. HTLV-1-transformed C81 cells were treated with LY294002 for 0, 3, 9 or 18 h and cell extracts were prepared for western blot analysis. As shown in Fig. 3A , while the overall level of Bad protein remained constant a significant decrease in the level of phosphorylation of Bad at Ser136 was observed. Consistent with previous results and as a control for these studies, AKT phosphorylation at Ser473 decreased with time and total AKT was constant (Fig. 3A , lower panels) (Jeong et al., 2005b) . A similar decrease in AKT phosphorylation at Thr308 was observed in these experiments (data not shown), consistent with previous findings (Jeong et al., 2005a) .
Phosphorylation of Bad at Ser136 inhibits the pro-apoptotic function of the protein by decreasing its interaction with Bcl-xL on the mitochondrial membrane. Given the decrease in Bad phosphorylation observed above, immunofluorescent staining of cytochrome c was conducted with C81 cells in the absence or presence of LY294002. Confocal microscopy revealed that, in untreated cells, cytochrome c was localized in a punctate pattern consistent with localization in the mitochondria (Fig. 3B , top left). In contrast, after treatment with LY294002, a diffuse distribution of cytochrome c was observed (Fig. 3B, top right) . The later staining pattern is consistent with the release of cytochrome c from the mitochondria to the cytosol. Control immunofluorescent assays with control IgG revealed no staining of the control or treated cells (data not shown). We further analyzed cytochrome c distribution by western blot analysis. The results of these studies demonstrated that the level of cytosolic cytochrome c was significantly increased in the LY294002-treated cells (data not shown).
LY294002-induced apoptosis is dependent on activity of caspase-9 in HTLV-1-transformed cells
Release of cytochrome c from the mitochondria is associated with caspase-9 activation (Garrido et al., 2006) . Moreover, AKT also directly inhibits the proteolytic activity of caspase-9 by phosphorylation of the protein at Ser136 (Cardone et al., 1998) . It was important, therefore, to test whether caspase-9 was activated in the LY294002-treated cells. To test the activation of caspase-9 in LY294002-induced apoptosis, we carried out chemiluminescent assays that specifically measure caspase-9 activity. LY294002 induced caspase-9 activation in a dosedependent manner (Fig. 4A) . Consistent with these findings, we observed the reduction of full-length caspase-9 protein following LY294002 treatment (Fig. 4B) . Coincident with the disappearance of full-length caspase-9, we observed the appearance of lower molecular weight cleavage products (data not shown). Trypan blue dye exclusion assays confirmed the importance of caspase-9 in the apoptosis pathway (Fig. 4C) . LY294002 treatment induced apoptosis in a time-dependent manner, with approximately 50% of the cells undergoing apoptosis by 72 h in this experiment. Pretreatment of the cells with either the caspase-9 specific or pan-specific inhibitor significantly reduced LY294002-induced apoptosis (Fig. 4C) . Together, the results suggest that LY294002-induced apoptosis involves the Bad/cytochrome c/caspase-9 mitochondria-dependent pathway.
LY294002 or SC-514-induced apoptosis is a p53-dependent pathway in HTLV-1-transformed cells p53, through its activity as a transcriptional activator or repressor, functions as a tumor suppressor inducing either cell cycle arrest or apoptosis in response to cellular stress (Oren, 2003; Vousden and Lu, 2002) . Previous studies from this laboratory demonstrated that AKT activation plays a critical role in the inhibition of p53 function in HTLV-1-transformed cells as treatment of C81 cells with LY294002 reactivated p53 transcription activity as measured by MDM2 promoter activity (Jeong et al., 2005b ). Therefore, we tested whether p53 plays a role in the LY294002-induced apoptosis. C81 cells were infected with Ad-GFP or Ad-p53 siRNA in the absence or presence of LY294002. As shown in Fig. 5A , infection of the cells with Adp53 siRNA significantly reduced p53 expression in the absence or presence of LY294002 (lanes 1, 3, and 4) . In contrast, infection of cells with the control Ad-GFP virus did not affect p53 expression (lanes 1 and 2) . As a control for these studies, we demonstrate that while LY294002 inhibited the phosphorylation of AKT, expression of AKT protein was not significantly affected by the infection with the Ad-GFP or Ad-p53 siRNA expressing virus (Fig. 5A, middle and bottom panel) . These results are consistent with previous studies using the p53 siRNA which demonstrated that the Ad-p53 siRNA specifically inhibits expression of p53, but not other cellular genes (Zhao et al., 2003) . The Ad-GFP virus infection serves as a control for any effect of adenovirus infection that may affect the experiment. Consistent with the results presented above, treatment of the cells with LY294002 decreased the level of phospho-AKT (S473). The decrease in AKT phosphorylation was similar in the Ad-p53 siRNA and Ad-GFP infected cells.
Lastly, trypan blue assays were used to measure cell viability with Ad-p53 siRNA infected C81 cells in the absence or presence of LY294002 (Fig. 5B) . In these studies, we also included cells which were treated with IKKβ specific inhibitor SC-514 (Kishore et al., 2003) . IKKβ was targeted since it is a direct substrate of AKT and plays an important role in NF-κB activation and inhibition of p53 in HTLV-1-transformed cells (Jeong et al., 2005a) . The results of these experiments demonstrate that infection of C81 cells with Ad-GFP or Adp53 siRNA caused a modest increase in cell death (Fig. 5B) . Addition of LY294002 or SC-514 to the control Ad-GFP infected cells resulted in a 3-to 5-fold increase in cell death. In contrast, addition of LY294002 or SC-514 to cells infected with Fig. 4 . LY294002-induced apoptosis is dependent on caspase-9 activity in HTLV-1-transformed cells. (A) Caspase-9 activity was measured by using Caspase Glo-9 assay systems (Promega). C81 cells (5 × 10 6 cells) were treated with 40 μM LY294002 for 24 h and harvested by centrifugation and supernatants were collected. Samples were gently mixed with Caspase Glo substrate and the luminescence of each sample was measured by using the Luciferase assay system. Error bars were calculated using three independent experiments. (B) Lysates were prepared from control or 40 μM LY294002-treated C81 cells and western blot analysis was performed to detect the expression of caspase-9 (Cell Signaling) as visualized by chemiluminescence. (C) C81 cells were treated with caspase inhibitors (100 μM) z-LEHD-FMK or Ac-DEVD-CHO for 1 h prior to treatment with 40 μM LY294002 for 0 to 72 h. Apoptosis was determined by the percentage of trypan blue positive cells. Fig. 5 . LY294002 or SC-514-induced apoptosis is p53-dependent pathway in HTLV-1-transformed cells. (A) C81 cells were infected with Ad-p53 siRNA or Ad-GFP in the absence or presence of 40 μM LY294002. After 72 h, cell lysates were prepared and western blot analysis was performed to detect the expression of p53 (Oncogene), phospho-AKT (Ser473) and AKT (Cell Signaling) as visualized by chemiluminescence. (B) Trypan blue dye exclusion assays were performed to measure apoptosis. C81 cells were infected with Ad-GFP or Ad-p53 siRNA in serum-free media. After 3 h, cells were harvested and resuspended in serumcontaining media and 40 μM LY294002 was added for indicated times.
Ad-p53 siRNA did not result in a significant increase in cell death. These results suggest that blocking AKT activation or its downstream target IKKβ leads to the induction of a p53-dependent apoptosis in C81 cells.
Discussion
Activation of the AKT pathway is common in many cancers and contributes to the inhibition of apoptosis and therapeutic resistance through multiple mechanisms (Nuutinen et al., 2006) . Consistent with these observations, inhibition of AKT decreases cell survival and potentiates the effects of chemotherapeutic drugs in cancer cells (Clark et al., 2002; Asselin et al., 2001b,a) . We and others have shown that AKT is activated in HTLV-1-transformed cells and plays an important role in cell survival. In part, the importance of AKT to cell survival is due to the regulation of multiple target pathways through phosphorylation of critical proteins. For example, phosphorylation of Bad by AKT inactivates the protein's ability to induce apoptosis, thus promoting cell survival. Conversely, dephosphorylation of Bad results in targeting of Bad to mitochondrial membranes where Bad interacts with and inactivates anti-apoptotic proteins Bcl-2 and Bcl-xL, inducing apoptosis (Datta et al., 1999) . We have previously shown that HTLV-1 Tax mediates activation of AKT by mediating phosphorylation at Ser473 and Thr308 (Jeong et al., 2005b) . In the present study, we demonstrate that blocking AKT by LY294002 decreased the phosphorylation of Bad. Since Bad regulates the mitochondrial release of cytochrome c (Yamaguchi et al., 2001) , cytochrome c localization was analyzed in C81 cells in the absence or presence of LY294002. Release of cytochrome c was observed both by immunofluorescent staining and western blot analysis (data now shown) of fractionated cell extracts. The best-defined target for cytochrome c is the apoptosome which is a multiprotein complex comprising Apaf-1, cytochrome c and caspase-9 that activates the apoptotic pathway (Zou et al., 1999) . In our studies, cleavage of caspase-9 was induced by LY294002 and pretreatment with a caspase-9 specific or pan caspase inhibitor significantly blocked LY294002-induced apoptosis (Fig. 4C) . These results suggest that, in HTLV-1-transformed cells, LY294002 induces apoptosis which is dependent on the dephosphorylation of Bad and activation of caspase-9.
Recent studies have demonstrated that AKT is also a signaling intermediate upstream of NF-κB dependent survival gene expression (Datta et al., 1999) . NF-κB activation requires phosphorylation of IκBα by IκB kinases (IKKs). IκBα phosphorylation targets IκBα for ubiquitination and proteolytic degradation (Baldwin, 1996; Beg and Baldwin, 1993) , releasing p50-p65 heterodimers to migrate to the nucleus and activate transcription. It has been shown that IKKs are a substrate of AKT and its ability to regulate NF-κB activity may be through direct interaction with IKKs as AKT can associate with the IKK complex in vivo (Datta et al., 1999) . In the present study, C81 cells were treated with SC-514, an IKKβ specific inhibitor (Kishore et al., 2003) . SC-514 induced apoptosis in HTLV-1-transformed cells to a level similar to that obtained with LY294002 treatment. Previous data from our laboratory have shown that LY294002 or SC-514 induced p53-dependent transcription. These results and data presented here argue that the AKT/IKKβ pathway plays a critical role in NF-κB activation and cell survival in HTLV-1-transformed cells.
Inactivation of the tumor suppressor protein p53 plays a critical role in tumorigenesis. p53 functions as an integrator of stress response signals by activating or repressing the transcription of genes that regulate cell cycle progression and/ or apoptosis (Appella and Anderson, 2001; Giaccia and Kastan, 1998; Meek, 1999; Prives and Hall, 1999) . Over the past several years, it has become evident that p53 and AKT are involved in a complex cross-talk that are at the core of the cell control machinery for switching between survival and death. This cross-talk is a combination of reciprocally antagonistic pathways emanating from p53 and AKT, which also involve tumor suppressor gene, PTEN, and oncogene, Mdm2 (Wee and Aguda, 2006) . We investigated whether p53 plays a role in the regulation of LY294002-mediated apoptosis and cell cycle arrest in HTLV-1-transformed cells. An adenovirus vector expressing a siRNA to p53 was utilized to specifically decrease expression of p53. The results of these studies clearly demonstrate that the Ad-p53 siRNA decreased LY294002-induced apoptosis. Thus, while activation of Bad and caspase-9 occurs in response to AKT inhibition, they are not sufficient to induce apoptosis, but must signal through the p53 pathway to induce apoptosis.
In a recent paper, Peloponese et al. suggested that Tax, in the absence of NF-κB activation, can activate activator protein-1 (AP-1) to promote cellular proliferation and survival through the PI3K/AKT pathway (Peloponese and Jeang, 2006) . These results are not inconsistent with our data, but focus more on the role of Tax-activated AKT in cell proliferation and provide intriguing data that Tax activates AKT through direct interaction with the p85 subunit of PI3K.
Following our original observation that AKT was activated in HTLV-1-transformed cells, Ikezoe et al. (2007) reported that the PI3K/AKT/mammalian target of rapamycin (mTOR) was activated in HTLV-1 cells. The authors demonstrated that rapamycin, the inhibitor of mTOR, induced growth inhibition and cell cycle arrest. Interestingly, the authors demonstrated that PI3K/AKT inhibitor LY294002 exhibited similar properties, inhibiting cell growth and inducing cell cycle arrest. When rapamycin was combined with LY294002, the ability of rapamycin to induce growth arrest and cause dephosphorylation of p70S6K and 4E-BP-1 was potentiated. It was suggested that the effect of LY294002 was due to its ability to block phosphorylation of AKT at Ser473, which was paradoxically induced by rapamycin.
In the present paper, we demonstrate that in HTLV-1-transformed cells AKT regulates pathways involved in cell cycle and cell viability. AKT phosphorylates or induces the phosphorylation of Bad, decreasing its ability to interact with and inhibit the function of Bcl-xL (Fig. 6) . AKT also induces NF-κB, which increases expression of Bcl-xL, an inhibitor of apoptosis. AKT regulates cell cycle progression through regulation of p27 and cyclin D1. While AKT likely regulates cyclin D1 expression through NF-κB, its interaction with p27 requires further investigation. Recent studies have focused on drug discovery targeting AKT and its downstream molecules in other human cancers. LY294002 effectively inhibits the growth of many types of tumor cells in vitro and in vivo and combining LY294002 with conventional chemotherapeutic agents may provide a treatment option for drug-resistant cancers. Poor solubility and high toxicity of LY294002 have stimulated the development of derivatives or specific AKT inhibitors including PX-866, IC486068, helenaquinone, perifosine and PX-316. AKT antagonist API-2 (AKT/PKB signaling inhibitor-2) has been shown to inhibit AKT kinase activity and to induce apoptosis in human cancer cells with high AKT activity . The results of this study suggest that these compounds may be considered useful in the treatment of ATL patients.
Materials and methods
Cell culture and drug treatment
HTLV-1-transformed C81 cells were maintained in RPMI supplemented with 10% fetal calf serum, 2 mM L-glutamine and penicillin (100 units/ml)/streptomycin (100 μg/ml). For treatment with LY294002, 5 × 10 6 cells were cultured in 10 ml of media in 100 mm dishes for the indicated times. Caspase inhibitors z-LEHD-FMK (100 μM) or Ac-DEVD-CHO (100 μM) were added 1 h prior to addition of LY294002. All drugs were obtained from Calbiochem.
LY294002 and AKT inhibitor II
AKT inhibitor LY294002 is a cell permeable, potent and specific phosphatidylinositol 3-kinase inhibitor that acts in the ATP binding site of the enzyme. AKT inhibitor II is a phosphatidylinositol analog that inhibits the activation of AKT without decreasing phosphorylation of upstream PDK-1.
Western blot analysis
Whole cell extracts were prepared by using lysis buffer (50 mM Tris-HCl pH 7.4, 120 mM sodium chloride, 5 mM EDTA, 0.5% Nonidet P-40, 50 mM sodium fluoride, 0.2 mM sodium vanadate and complete protease inhibitor from Roche Diagnostics) at a cell concentration of 10 7 cells/ml. The extracts were incubated on ice for 15 min, centrifuged (10,000×g) at 4°C for 10 min, and supernatants were collected. Protein concentrations were determined by Bradford assay (Bio-Rad), and 50-100 μg protein was separated by electrophoresis in 4 to 20% Tris-glycine gels (Novex). The proteins were then transferred to PVDF membranes (Immobilon) and western blot analysis performed with the indicated antibodies. PhosphoBad (Ser136), Bad, Bax, phospho-AKT (Ser473), AKT, Caspase-9, p27 and cyclin D1 antibodies were obtained from Cell Signaling. p21 and Cyclin E antibodies were obtained from Santa Cruz Biotechnologies.
Immunofluorescent staining
Following treatment with LY294002 (40 μM), C81 cells were placed on lysine coated coverslips, fixed in PBS-buffered 4% paraformaldehyde and permeabilized in cold methanol. The permeabilized cells were incubated with 10% normal goat serum in PBS for 1 h followed by immunostaining with anticytochrome c antibody (Active Motif) and an Alexa Fluor 488-conjugated anti-mouse IgG antibody. The immunostained cells were mounted in mounting medium containing DAPI (Vectashield, Vector Labs) and were visualized by a Leica confocal microscope.
Cell viability
Cell viability was determined either by trypan blue staining or the CellTiter-Glo ATP assay. In the trypan blue assay, cells were stained with 0.4% trypan blue solution (Quality Biotech) for 1 min. Cells that took up trypan blue were counted as dead cells and expressed as a percentage of the total cell number. Alternatively, cell viability assay was determined using CellTiter-Glo luminescent cell viability assay from Promega using the manufacturer's instruction. Briefly, 1-2 × 10 5 cells were cultured in sterile 96 well culture plates in the presence of appropriate concentration of LY294002 (20-80 μM) in 100 μl of RPMI media. The plates were then incubated for the time indicated. One hundred microliters of CellTiter-Glo reagent was added to lyse the cells. The contents were mixed in an orbital shaker for 2 min and then incubated at room temperature for 10 min. The luminescence was then recorded in a luminometer with an integration time of 1 s per well. The luminescent signals for the LY294002-treated cells were normalized to the luminescent signal of cells treated with DMSO which was arbitrarily set to 1. Blocking AKT function using LY294002 results in decreased phosphorylation of Bad, cytochrome c release, caspase-9 activation and apoptosis. LY294002 treatment also blocks AKT dependent phosphorylation of the IKKβ, resulting in a decrease in NF-κB binding and transcription activity. Apoptosis is dependent upon p53 activity as indicated by the ability of an siRNA to p53 to inhibit apoptosis.
Analysis of caspase-9 activity
Caspase-9 activity was measured by using Caspase Glo-9 assay systems (Promega). Briefly, C81 cells (5 × 10 6 cells/10 ml) were treated with 40 μM LY294002 for 24 h. Cells were harvested by centrifugation and supernatants were collected. Samples (100 μl) were gently mixed with Caspase Glo substrate (100 μl) and the luminescence of each sample was measured by using Luciferase assay system (Promega).
Adenovirus infection of cells
The pAdTrack-si/p53 (Ad-p53 siRNA) construct was kindly provided by Dr. Ling-Jun Zhao (St. Louis University) and pAd-GFP was purchased from Q-Biogene. The recombinant viral genome was linearized with PacI and transfected into 293 cells in a 60-mm dish using PolyFect transfection reagent (Qiagen). Eight days after transfection, the recombinant virus was collected and subjected to one round of amplification by infecting 1.5 × 10 6 293 cells, yielding 2 ml of viral stocks. Infection of 293 cells was performed in serum free DMEM. Following viral infection, 293 cells were maintained in DMEM with 10% fetal bovine serum. HTLV-1-transformed C81 cells (1.5 × 10 6 ) in a 60-mm dish were infected with either Ad-p53 siRNA or Ad-GFP in serum-free RPMI media. After 3 h, cells were resuspended in media containing 10% fetal calf serum. LY294002 (40 μM) was added and incubations carried out at as indicated.
Cell cycle analysis
Adenoviral infected C81 cells with or without LY294002 were harvested and fixed in 70% ethanol. The fixed cells were then stained with propidium iodide (50 μg/ml) after treatment with RNase (5 μg/ml). The stained cells were analyzed for DNA content in FACSCalibur (Becton Dickinson) using the Cell Quest program (Becton Dickinson). The resultant data were analyzed by ModFit LT (Verity Software House) using appropriate gates.
